Enteric Coated Tablets
Enteric Coated Tablets - Related Videos
10:13
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
0 Views •
Cited by 11 •
2014
We tested the usability of a tablet-computer-based application (EmoCogMeter) in investigating the effects of age on cognition. Results show an age-related cognitive decline, thereby proving the usability of our application. Findings underline the great clinical and practical potential of a tablet-based application for detection and monitoring of cognitive dysfunction.
10:10
Evaluating Tests of Cognition using a Computerized Touch-Sensitive Tablet, Eye Tracking, and Functional Magnetic Resonance Imaging
0 Views •
2026
A protocol for simultaneous recording of visuomotor behavior and brain activity during standard paper-based cognitive tests using an MRI-compatible tablet and eye-tracking technology alongside functional MRI, towards improving the usage of such tests. Preliminary results are presented from a young healthy adult performing a Trail-Making test.
05:44
Formation of Dispersible Taohong Siwu Tablets
0 Views •
2023
This article discusses the process used to formulate and prepare Taohong Siwu, a traditional Chinese medicine, as a dispersible tablet. We performed single-factor and orthogonal experiments to screen the prescription excipients, optimize the formulation process, and produce dispersible Taohong Siwu tablets.
11:26
In Situ Ca2+ Imaging of the Enteric Nervous System
0 Views •
Cited by 24 •
2015
The enteric nervous system (ENS) is a network of neurons and glia located in the gut wall that controls intestinal reflexes. This protocol describes methods for recording the activity of enteric neurons and glia in live preparations of ENS using Ca2+ imaging.
01:18
Drug Delivery: Enteral Route
0 Views •
2024
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs. Drugs in...
FAQs
The coating acts as a pH-dependent gate: it must remain intact during exposure to gastric acid, then dissolve at the higher pH encountered in the small intestine. This sequence separates passage through the stomach from active-ingredient release. Coating performance therefore influences whether delivery is delayed appropriately and whether the drug reaches its intended intestinal site.
Enteric coating can serve two distinct clinical purposes. It may protect an acid-sensitive active ingredient from degradation before intestinal delivery, or it may reduce direct exposure of the stomach to a drug that could cause gastric irritation. The same dosage-form strategy therefore supports either drug stability, patient tolerability, or both, depending on the formulation goal.
If the coating loses integrity under acidic gastric conditions, the active ingredient may be released before reaching the intestine, reducing the intended protection or delay. If it does not dissolve when exposed to the higher intestinal pH, release may occur later than intended. Evaluating both stages is essential for consistent site-specific delivery and therapeutic performance.
Release location connects dosage-form design with drug stability and absorption. Keeping the active ingredient enclosed during gastric passage can protect it from acidic conditions, while intestinal release places the ingredient at the site identified for subsequent absorption. For this reason, the coating is evaluated not only for physical integrity but also for its effect on delivery and therapeutic performance.
Evaluation follows the intended pH sequence. The tablet and coating are first assessed under acidic gastric conditions to determine whether the barrier remains intact. Testing then examines behavior at the higher pH associated with the small intestine, including dissolution and active-ingredient release. These observations show whether the formulation provides the planned delay and intestinal delivery.
They are useful when a formulation must delay release until the intestine, protect an acid-sensitive drug during gastric transit, or reduce gastric irritation. Their design can also support site-specific delivery and influence the conditions under which absorption occurs. Selection should therefore reflect the drug’s stability, the desired release location, and the intended therapeutic performance.
Assessment should address more than whether the tablet eventually releases its active ingredient. Important outcomes include stability during gastric exposure, dissolution after intestinal exposure, the location and timing of release, and the resulting therapeutic performance. Together, these measures indicate whether the coating fulfills its protective or delayed-delivery purpose in the clinical formulation.